PharmaShots | Incisive News in 3 Shots

Subscribe Now

Squamous Cell Carcinoma

The US FDA Declines to Approve Incyte's Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal

The US FDA Declines to Approve Incyte's Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal

July 26, 2021

Merck's Keytruda (pembrolizumab) Receives Two New PMDA's Approvals in Japan

Merck's Keytruda (pembrolizumab) Receives Two New PMDA's Approvals in Japan

August 25, 2020

EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head and Neck

EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of...

March 13, 2020

Regeneron and Sanofi's Libtayo (cemiplimab) Receives European Commission's Approval for Advanced Cutaneous Squamous Cell Carcinoma

Regeneron and Sanofi's Libtayo (cemiplimab) Receives European Commission's Approval for Advanced Cutaneous Squamous Cell Carcinoma

July 2, 2019

Merck's Keytruda (pembrolizumab) Receives FDA's Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives FDA's Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Sq...

June 11, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us